Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711446 | 0.85 | CNR1 (0.64) | CNR1L3MBTL1KCNH2SMN1; SMN2GAA | |
| SCHEMBL4274475 | 0.83 | CNR1 (0.65) | CNR1L3MBTL1PKMKCNH2SMN1; SMN2 | |
| SCHEMBL4275859 | 0.82 | CNR1 (0.62) | CNR1L3MBTL1KCNH2GAA | |
| SCHEMBL4266825 | 0.78 | CNR1 (0.88) | CNR1L3MBTL1PKMKCNH2 | |
| SCHEMBL752819 | 0.78 | PKM (0.62) | PKMGAA | |
| SCHEMBL4265815 | 0.77 | CNR1 (1.00) | CNR1L3MBTL1KCNH2 | |
| SCHEMBL4270479 | 0.76 | L3MBTL1 (0.80) | CNR1L3MBTL1SMN1; SMN2GAA | |
| SCHEMBL4270143 | 0.76 | CNR1 (0.72) | CNR1L3MBTL1PKMKCNH2GAA | |
| SCHEMBL4267158 | 0.76 | CNR1 (1.00) | CNR1L3MBTL1PKMKCNH2 | |
| SCHEMBL1947016 | 0.75 | L3MBTL1 (1.00) | CNR1L3MBTL1KCNH2SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885L3MBTL1 3894/4885PKM 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.